The High Cost of Progress: Delcath's Liver Cancer Device Raises Questions About Sustainability Delcath Systems' recent second quarter results show a clear trend: its liver cancer treatment is gaining popularity, but at what cost?
Revenue has increased by 20% to $29. 1 million, with the number of HEPZATO procedures rising by 30%. However, expenses are also on the rise, threatening the company's financial sustainability.
The key driver of growth is Delcath's liver directed chemotherapy delivery system, HEPZATO KIT. This device has generated $27. 1 million in revenue, up from $22. 5 million last year.